Turning cold tumors hot: from molecular mechanisms to clinical applications

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

The Immune Landscape of Cancer

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520

Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270

Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid

Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy

Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.49 · Cited by 2,251

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008

B cells are associated with survival and immunotherapy response in sarcoma

Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942

Turning foes to friends: targeting cancer-associated fibroblasts

Chen, X., & Song, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,929

Tertiary lymphoid structures in the era of cancer immunotherapy

Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757

Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults

Bhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D. A., & Smeeth, L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60892-8 · Cited by 1,707

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679

Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes

Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.008 · Cited by 1,577

Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539

Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer

Kather, J. N., Pearson, A. T., Halama, N., Jäger, D., Krause, J., Loosen, S. H., Marx, A., Boor, P., Tacke, F., Neumann, U. P., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0462-y · Cited by 1,458

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407

Pan-cancer single-cell landscape of tumor-infiltrating T cells

Zheng, L., Qin, S., Si, W., Wang, A., Xing, B., Gao, R., Ren, X., Wang, L., Wu, X., Zhang, J., et al. (2021) · Science · doi:10.1126/science.abe6474 · Cited by 1,402

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370

Metabolic support of tumour-infiltrating regulatory T cells by lactic acid

Watson, M. J., Vignali, P., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,319

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

André, P., Denis, C., Soulas, C., Bourbon, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,257

Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I

Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Sun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30413-3 · Cited by 1,236

CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness

Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230

PI3Kγ is a molecular switch that controls immune suppression

Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,219

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201

The microbiome, cancer, and cancer therapy

Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H. C., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,155

A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity

Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142

Cold Tumors: A Therapeutic Challenge for Immunotherapy

Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau‐Guilemond, J., Valsesia‐Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,140

Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

Beltra, J., Manne, S., Abdel-Hakeem, M. S., Kurachi, M., Giles, J. R., Chen, Z., Casella, V., Ngiow, S. F., Khan, O., Huang, Y., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.014 · Cited by 1,139

Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma

Ji, A. L., Rubin, A. J., Thrane, K., Jiang, S., Reynolds, D. L., Meyers, R. M., Guo, M. G., George, B. M., Mollbrink, A., Bergenstråhle, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.039 · Cited by 1,117

Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma

Li, H., van der Leun, A. M., Yofe, I., Lubling, Y., Gelbard-Solodkin, D., van Akkooi, A. C. J., van den Braber, M., Rozeman, E. A., Haanen, J. B. A. G., Blank, C. U., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.043 · Cited by 1,101

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

Motz, G. T., Santoro, S. P., Wang, L., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,074

Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., Miller, R. E., Riaz, N., Douillard, J.-Y., André, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz116 · Cited by 1,057

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E. W., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,051

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability

Ma, X., Xiao, L., Liu, L., Ye, L., Pan, S., Bi, E., Wang, Q., Yang, M., Qian, J., & Yi, Q. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.015 · Cited by 1,048

Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment

Ma, X., Bi, E., Lu, Y., Su, P., Huang, C., Liu, L., Wang, Q., Yang, M., Kalady, M. F., Qian, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.002 · Cited by 1,033

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021

Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells

Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., Huang, X., Liu, Y., Wang, J., Dougherty, U., et al. (2019) · Nature · doi:10.1038/s41586-019-0916-x · Cited by 955

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment

Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Ghamry-Barrin, S., Kantari‐Mimoun, C., Bercovici, N., Guérin, M. V., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 941

Phagocytosis checkpoints as new targets for cancer immunotherapy

Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y., & Weissman, I. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0183-z · Cited by 937

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H. E., Roelli, P., Utzschneider, D. T., von Hoesslin, M., Cullen, J. G., Fan, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1326-9 · Cited by 930

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Kahles, A., Lehmann, K.-V., Toussaint, N. C., Hüser, M., Stark, S. G., Sachsenberg, T. T., Stegle, O., Kohlbacher, O., Sander, C., Johnson, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.001 · Cited by 914

Design of amidobenzimidazole STING receptor agonists with systemic activity

Ramanjulu, J. M., Pesiridis, G. S., Yang, J., Concha, N., Singhaus, R., Zhang, S.-Y., Tran, J.-L., Moore, P., Lehmann, S., Eberl, H. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0705-y · Cited by 912

β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0349-y · Cited by 903

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875

Management of toxicities of immune checkpoint inhibitors

Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835

Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors

Xu, S., Chaudhary, O., Rodríguez-Morales, P., Sun, X., Chen, D., Zappasodi, R., Xu, Z. Z., Pinto, A. F. M., Williams, A. E., Schulze, I., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.003 · Cited by 834

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells

Jansen, C. S., Prokhnevska, N., Master, V. A., Sanda, M. G., Carlisle, J. W., Bilen, M. A., Cardenas, M. A., Wilkinson, S. C., Lake, R. G., Sowalsky, A. G., et al. (2019) · Nature · doi:10.1038/s41586-019-1836-5 · Cited by 826

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817

TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 + T cell exhaustion

Seo, H., Chen, J., González-Avalos, E., Samaniego-Castruita, D., Das, A., Wang, Y. H., López-Moyado, I. F., Georges, R. O., Zhang, W., Onodera, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905675116 · Cited by 808

A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer

Wagner, J., Rapsomaniki, M., Chevrier, S., Anzeneder, T., Langwieder, C., Dykgers, A., Rees, M., Ramaswamy, A., Muenst, S. E., Soysal, S. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.005 · Cited by 807

Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity

Ringel, A. E., Drijvers, J. M., Baker, G. J., Catozzi, A., García-Cañaveras, J. C., Gassaway, B. M., Miller, B. C., Juneja, V. R., Nguyen, T. H., Joshi, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.009 · Cited by 780

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770

Peripheral T cell expansion predicts tumour infiltration and clinical response

Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 746

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735

Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity

He, Y., Fu, L., Li, Y., Wang, W., Gong, M., Zhang, J., Dong, X., Huang, J., Wang, Q., Mackay, C. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.002 · Cited by 729

WNT/β-catenin pathway activation correlates with immune exclusion across human cancers

Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722

The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

Dammeijer, F. F., van Gulijk, M., Mulder, E. E. A. P., Lukkes, M. M., Klaase, L., van den Bosch, T. P. P., van Nimwegen, M., Lau, S. P., Latupeirissa, K., Schetters, S. T. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.001 · Cited by 718

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Huang, A. C. C., Orlowski, R. J., Xu, X., Mick, R., George, S. M., Yan, P., Manne, S., Kraya, A., Wubbenhorst, B. S., Dorfman, L. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0357-y · Cited by 696

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

Wang, H., Franco, F., Tsui, Y.-C., Xie, X., Trefny, M. P., Zappasodi, R., Mohmood, S. R., Fernández-García, J., Tsai, C.-H., Schulze, I., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0589-5 · Cited by 694

An orally available non-nucleotide STING agonist with antitumor activity

Pan, B.-S., Perera, S. A., Piesvaux, J. A., Presland, J. P., Schroeder, G. K., Cumming, J. N., Trotter, B. W., Altman, M. D., Buevich, A. V., Cash, B., et al. (2020) · Science · doi:10.1126/science.aba6098 · Cited by 694

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A. J., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 671

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30078-0 · Cited by 664

Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis

Fu, Y., Jung, A. W., Viñas, R., González, S., Vöhringer, H. S., Shmatko, A., Yates, L. R., Jimenez‐Liñan, M., Moore, L., & Gerstung, M. (2020) · Nature Cancer · doi:10.1038/s43018-020-0085-8 · Cited by 655

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

Lu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, M. A., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 632

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

Latham, A. J., Srinivasan, P., Kemel, Y. M., Shia, J., Bandlamudi, C., Mandelker, D. L., Middha, S., Hechtman, J. F., Zehir, A., Dubard-Gault, M. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00283 · Cited by 623

KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617

Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment

Lam, K. C., Araya, R. E., Huang, A., Chen, Q., Di Modica, M., Rodrigues, R. R., Lopès, A., Johnson, S. B., Schwarz, B., Bohrnsen, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.019 · Cited by 604

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers

Scheper, W., Kelderman, S., Fanchi, L. F., Linnemann, C., Bendle, G. M., de Rooij, M. A. J., Hirt, C., Mezzadra, R., Slagter, M., Dijkstra, K. K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0266-5 · Cited by 583

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

Theelen, W. S. M. E., Chen, D., Verma, V., Hobbs, B. P., Peulen, H. M. U., Aerts, J. G. J. V., Bahce, I., Niemeijer, A.-L. N., Chang, J. Y., de Groot, P. M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30391-x · Cited by 574

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

Oliveira, G., Stromhaug, K., Klaeger, S., Kula, T., Frederick, D. T., Le, P. M., Forman, J., Huang, T., Li, S., Zhang, W., et al. (2021) · Nature · doi:10.1038/s41586-021-03704-y · Cited by 569

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

Yarchoan, M. M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 565

Improving immune–vascular crosstalk for cancer immunotherapy

Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

Hu, Z., Leet, D., Allesøe, R. L., Oliveira, G., Li, S., Luoma, A., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01206-4 · Cited by 560

Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

Mandal, R., Samstein, R. M., Lee, K.-W., Havel, J. J., Wang, H., Krishna, C., Sabio, E. Y., Makarov, V., Kuo, F., Blecua, P., et al. (2019) · Science · doi:10.1126/science.aau0447 · Cited by 554

T cell stemness and dysfunction in tumors are triggered by a common mechanism

Vodnala, S. K., Eil, R., Kishton, R. J., Sukumar, M., Yamamoto, T. N., Ha, N.-H., Lee, P.-H., Shin, M., Patel, S. J., Yu, Z., et al. (2019) · Science · doi:10.1126/science.aau0135 · Cited by 552

Noncoding regions are the main source of targetable tumor-specific antigens

Laumont, C. M., Vincent, K., Hesnard, L., Audemard, E. O., Bonneil, É., Laverdure, J., Gendron, P., Courcelles, M., Hardy, M., Côté, C., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5516 · Cited by 537

When worlds collide: Th17 and Treg cells in cancer and autoimmunity

Knochelmann, H. M., Dwyer, C. J., Bailey, S. R., Amaya, S. M., Elston, D. M., Mazza-McCrann, J. M., & Paulos, C. M. (2018) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0004-4 · Cited by 535

The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies

Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 523

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Tavazoie, M. F., Pollack, I., Tanqueco, R., Ostendorf, B. N., Reis, B. S., Gonsalves, F. C., Kurth, I., Andreu-Agullo, C., Derbyshire, M. L., Posada, J., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.026 · Cited by 476

Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel

Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7098 · Cited by 471

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462

Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment

Zheng, Y., Chen, Z., Han, Y., Li, H., Zou, X., Zhou, B., Hu, R., Hao, J., Bai, S., Xiao, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20019-0 · Cited by 459

B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity

Zhang, B., Vogelzang, A., Miyajima, M., Sugiura, Y., Wu, Y., Chamoto, K., Nakano, R., Hatae, R., Menzies, R. J., Sonomura, K., et al. (2021) · Nature · doi:10.1038/s41586-021-04082-1 · Cited by 455

NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death

Huang, D., Chen, J., Yang, L., Ouyang, Q., Li, J., Lao, L., Zhao, J., Liu, J., Lu, Y., Xing, Y., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0207-y · Cited by 445

Lipid signalling enforces functional specialization of Treg cells in tumours

Lim, S. A., Wei, J., Nguyen, T.-L. M., Shi, H., SU, W. W., Palacios, G. F., Dhungana, Y., Chapman, N. M., Long, L., Saravia, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03235-6 · Cited by 434

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?

Strickler, J. H., Hanks, B. A., & Khasraw, M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3054 · Cited by 430

Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion

Sun, X., Wu, B., Chiang, H.-C., Deng, H., Zhang, X., Xiong, W., Liu, J., Rozeboom, A. M., Harris, B. T., Blommaert, E., et al. (2021) · Nature · doi:10.1038/s41586-021-04057-2 · Cited by 429

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

Toulmonde, M., Penel, N., Adam, J., Chevreau, C., Blay, J., Cesne, A. L., Bompas, E., Piperno-Neumann, S., Cousin, S., Grellety, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1617 · Cited by 420

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis

Mathewson, N. D., Ashenberg, O., Tirosh, I., Gritsch, S., Perez, E. M., Marx, S., Jerby‐Arnon, L., Chanoch-Myers, R., Hara, T., Richman, A. R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.022 · Cited by 415

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

Spranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Yan, L., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 403

Tumor neoantigens: from basic research to clinical applications

Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 401

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours

Zappasodi, R., Serganova, I. S., Cohen, I., Maeda, M., Shindo, M., Şenbabaoğlu, Y., Watson, M. J., Leftin, A., Maniyar, R. R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 401

Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7431 · Cited by 394

Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study

Yamashita, R., Long, J., Longacre, T., Peng, L., Berry, G., Martin, B., Higgins, J., Rubin, D. L., & Shen, J. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30535-0 · Cited by 391

Immunogenic neoantigens derived from gene fusions stimulate T cell responses

Yang, W., Lee, K.-W., Srivastava, R. M., Kuo, F., Krishna, C., Chowell, D., Makarov, V., Hoen, D. R., Dalin, M. G., Wexler, L. H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0434-2 · Cited by 381

Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity

Yang, H., Xia, L., Chen, J., Zhang, S., Martin, V., Li, Q., Lin, S., Chen, J., Calmette, J., Lu, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0566-4 · Cited by 379

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

Zhou, T., Damsky, W., Weizman, O.-E., McGeary, M. K., Hartmann, K. P., Rosen, C. E., Fischer, S., Jackson, R. P., Flavell, R. A., Wang, J., et al. (2020) · Nature · doi:10.1038/s41586-020-2422-6 · Cited by 377

STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth

Zhang, C., Yue, C., Herrmann, A., Song, J., Egelston, C. A., Wang, T., Zhang, Z., Li, W., Lee, H., Aftabizadeh, M., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.013 · Cited by 376

BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells

Seo, H., González‐Avalos, E., Zhang, W., Ramchandani, P., Yang, C., Lio, C. J., Rao, A., & Hogan, P. G. (2021) · Nature Immunology · doi:10.1038/s41590-021-00964-8 · Cited by 354

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01211-7 · Cited by 349

Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer

Kichenadasse, G., Miners, J. O., Mangoni, A. A., Rowland, A., Hopkins, A. M., & Sorich, M. J. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5241 · Cited by 339

Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity

Hutton, C., Heider, F., Blanco-Gomez, A., Banyard, A., Kononov, A., Zhang, X., Karim, S., Paulus-Hock, V., Watt, D., Steele, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.017 · Cited by 337

β2 adrenergic receptor–mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells

Mohammadpour, H., MacDonald, C. R., Qiao, G., Chen, M., Dong, B., Hylander, B. L., McCarthy, P. L., Abrams, S. I., & Repasky, E. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129502 · Cited by 328

Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression

Huang, D., Wang, Y., Thompson, J. W., Yin, T., Alexander, P. B., Qin, D., Mudgal, P., Wu, H., Liang, Y., Tan, L., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00820-9 · Cited by 323

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Vernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0030 · Cited by 319

Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition

Ennishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1090 · Cited by 318

Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer

Overacre-Delgoffe, A. E., Bumgarner, H. J., Cillo, A. R., Burr, A. H. P., Tometich, J. T., Bhattacharjee, A., Bruno, T. C., Vignali, D. A. A., & Hand, T. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.003 · Cited by 318

A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients

Cursons, J., Souza-Fonseca-Guimarães, F., Foroutan, M., Anderson, A., Hollande, F., Hediyeh-zadeh, S., Behren, A., Huntington, N. D., & Davis, M. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0500 · Cited by 312

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

Dieci, M. V., Mathieu, M. C., Guarneri, V., Conte, P., Delaloge, S., André, F., & Goubar, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv239 · Cited by 310

Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages

Su, S., Zhao, J., Xing, Y., Zhang, X., Liu, J., Ouyang, Q., Chen, J., Su, F., Liu, Q., & Song, E. (2018) · Cell · doi:10.1016/j.cell.2018.09.007 · Cited by 309

The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z. G., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1259 · Cited by 303

β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy

Bucsek, M. J., Qiao, G., MacDonald, C. R., Giridharan, T., Evans, L., Niedzwecki, B., Liu, H., Kokolus, K. M., Eng, J. W.-L., Messmer, M. N., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0546 · Cited by 294

Humanized Mice for the Study of Immuno-Oncology

Rochère, P. D. L., Guil‐Luna, S., Decaudin, D., Azar, G. A., Sidhu, S., & Piaggio, E. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.07.001 · Cited by 292

DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285

Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death

Hayashi, K., Nikolos, F., Lee, Y. C., Jain, A., Tsouko, E., Gao, H., Kasabyan, A., Leung, H. E., Osipov, A., Jung, S. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19970-9 · Cited by 282

The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake

Pulido, Á. D. M., Hänggi, K., Celias, D. P., Gardner, A., Li, J., Bittencourt, B. M. B., Mohamed, E. T., Trillo-Tinoco, J., Osunmakinde, O., Peña, R. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.019 · Cited by 282

Gut microbiota modulate T cell trafficking into human colorectal cancer

Cremonesi, E., Governa, V., Garzon, J. F. G., Mele, V., Amicarella, F., Muraro, M. G., Trella, E., Galati-Fournier, V., Oertli, D., Däster, S. R., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313498 · Cited by 275

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273

Turning up the heat on non-immunoreactive tumours: opportunities for clinical development

de Olza, M. O., Rodrigo, B. N., Zimmermann, S., & Coukos, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30234-5 · Cited by 262

Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment

Acharya, N., Madi, A., Zhang, H., Klapholz, M., Escobar, G., Dulberg, S., Christian, E., Ferreira, M., Dixon, K. O., Fell, G. G., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.005 · Cited by 257

Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma

Ding, G., Ma, J., Yun, J., Chen, X., Yu, L., Zhang, S., Shi, J.-Y., Chang, Y., Ji, Y., Wang, X., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.030 · Cited by 256

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy

Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7881 · Cited by 255

Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics

Choi, Y. S., Bae, S., Chang, J. H., Kang, S., Kim, S. H., Kim, J., Rim, T. H., Choi, S. H., Jain, R., & Lee, S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa177 · Cited by 255

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Montesion, M., Murugesan, K., Jin, D. X., Sharaf, R., Sánchez, N., Guria, A., Minker, M., Li, G., Fisher, V. A., Sokol, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0672 · Cited by 253

Tumor innervation: peripheral nerves take control of the tumor microenvironment

Gysler, S. M., & Drapkin, R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147276 · Cited by 230

Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer

Su, S., Liao, J., Liu, J., Huang, D., He, C., Chen, F., Yang, L., Wu, W., Chen, J., Lin, L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.34 · Cited by 227

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

Mlecnik, B., Bifulco, C. B., Bindea, G., Marliot, F., Lugli, A., Lee, J. J., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03205 · Cited by 211

Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

Berry, S., Giraldo, N. A., Green, B., Cottrell, T. R., Stein, J. E., Engle, E. L., Xu, H., Ogurtsova, A., Roberts, C. A., Wang, D., et al. (2021) · Science · doi:10.1126/science.aba2609 · Cited by 202

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy

Bai, X. L., Hu, J., Warner, A. B., Quach, H. T., Cann, C., Zhang, M. Z., Si, L., Tang, B., Cui, C., Yang, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1283 · Cited by 191

Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis

Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 175

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

Horton, B. L., Williams, J. B., Cabanov, A., Spranger, S., & Gajewski, T. F. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0249 · Cited by 170

Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance

Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 166

Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma

Melaiu, O., Chierici, M., Lucarini, V., Jurman, G., Conti, L. A., Vito, R. D., Boldrini, R., Cifaldi, L., Castellano, A., Furlanello, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19781-y · Cited by 164

Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers

Song, X., Zhou, Z., Li, H., Xue, Y., Lu, X., Bahar, İ., Kepp, O., Hung, M., Kroemer, G., & Wan, Y. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0402 · Cited by 160

mRNA Delivery of a Bispecific Single‐Domain Antibody to Polarize Tumor‐Associated Macrophages and Synergize Immunotherapy against Liver Malignancies

Wang, Y., Tiruthani, K., Li, S., Hu, M., Zhong, G., Tang, Y., Roy, S., Zhang, L., Tan, J. H., Liao, C., et al. (2021) · Advanced Materials · doi:10.1002/adma.202007603 · Cited by 145

Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity

Giampazolias, E., Schulz, O., Lim, K. H. J., Rogers, N. C., Chakravarty, P., Srinivasan, N., Gordon, O., Cardoso, A., Buck, M. D., Poirier, E. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.021 · Cited by 137

Sex Hormones and Anticancer Immunity

Özdemir, B. C., & Dotto, G. P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0137 · Cited by 134

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.014 · Cited by 133

Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer

Kießler, M., Plesca, I., Sommer, U. J., Wehner, R., Wilczkowski, F., Müller, L., Tunger, A., Lai, X., Rentsch, A., Peuker, K., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001813 · Cited by 129

Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

Liu, Z., Zhou, Q., Wang, Z., Zhang, H., Zeng, H., Huang, Q., Chen, Y., Jiang, W., Lin, Z., Qu, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000978 · Cited by 125

High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity

Vries, N. L. D., van Unen, V., Ijsselsteijn, M. E., Abdelaal, T., van der Breggen, R., Sarasqueta, A. F., Mahfouz, A. E., Peeters, K. C. M. J., Höllt, T., Lelieveldt, B. P. F., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318672 · Cited by 118

Turning tumors from cold to inflamed to improve immunotherapy response

Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 118

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

Ng, H. H. M., Lee, R. Y., Goh, S., Tay, I. S. Y., Lim, X., Lee, B. T. K., Chew, V., Li, H., Tan, B., Lim, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000987 · Cited by 115

Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer

Huang, D., Chen, X., Zeng, X., Lao, L., Li, J., Xing, Y., Lu, Y., Ouyang, Q., Chen, J., Yang, L., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00939-9 · Cited by 114

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment

Qi, Z., Xu, Z., Zhang, L., Zou, Y., Li, J., Yan, W., Li, C., Liu, N., & Wu, H. (2022) · Nature Communications · doi:10.1038/s41467-021-27833-0 · Cited by 114

Future prospects for CD8+ regulatory T cells in immune tolerance

Flippe, L., Bézie, S., Anegón, I., & Guillonneau, C. (2019) · Immunological Reviews · doi:10.1111/imr.12812 · Cited by 98

Obesity-Associated Myeloid-Derived Suppressor Cells Promote Apoptosis of Tumor-Infiltrating CD8 T Cells and Immunotherapy Resistance in Breast Cancer

Gibson, J. T., Orlandella, R. M., Turbitt, W. J., Behring, M. P., Manne, U., Sorge, R. E., & Norian, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590794 · Cited by 81

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy

Simon, S., Voillet, V., Vignard, V., Wu, Z., Dabrowski, C., Jouand, N., Beauvais, T., Khammari, A., Braudeau, C., Josien, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001631 · Cited by 79

Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles

Wu, M., Mei, F., Liu, W., & Jiang, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109637 · Cited by 65

The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer

Liu, J., Lao, L., Chen, J., Jiang, L., Zeng, W., Zhu, X., Li, J., Chen, X., Yang, L., Xing, Y., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00196-7 · Cited by 59

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma

Lee, M. H., Järvinen, P., Nísen, H., Brück, O. E., Ilander, M., Uski, I., Theodoropoulos, J., Kankainen, M., Mirtti, T. K., Mustjoki, S. M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.1993042 · Cited by 32

Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation

Milling, L. E., Garafola, D., Agarwal, Y., Wu, S., Thomas, A., Donahue, N. D., Adams, J., Thai, N., Suh, H., & Irvine, D. J. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0247 · Cited by 29

Cold and hot tumors: from molecular mechanisms to targeted therapy

Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811

CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential

Koh, C., Lee, S., Kwak, M., Kim, B., & Chung, Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01105-x · Cited by 379

Tertiary lymphoid structures in anticancer immunity

Teillaud, J., Houel, A., Panouillot, M., Riffard, C., & Dieu‐Nosjean, M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 322

Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides

Huang, D., Zhu, X., Ye, S., Zhang, J., Liao, J., Zhang, N., Zeng, X., Wang, J., Yang, B., Zhang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06834-7 · Cited by 222

Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer

Chen, Y., Wang, D., Li, Y., Lu, Q., Si, W., Bo, Y., Chen, X., Ye, Z., Fan, H., Liu, B., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.009 · Cited by 229

Cold and hot tumors: from molecular mechanisms to targeted therapy

Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811

Immunologic tumor microenvironment modulators for turning cold tumors hot

Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · 癌症：英文版 · doi:10.1002/cac2.12539 · Cited by 403

Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors

Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 123

Turning cold tumors into hot tumors to ignite immunotherapy

Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 124

Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition

Chen, W., Ma, Y., Wang, F., Liao, Y., Chen, Y., Zhao, B., Zhao, Q., Wang, D., & Tang, D. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221120708 · Cited by 31